

Christopher H Van Dyck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8032884/publications.pdf>

Version: 2024-02-01

93
papers

4,768
citations

147566
31
h-index

102304
66
g-index

106
all docs

106
docs citations

106
times ranked

6311
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-Amyloid- β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. <i>Biological Psychiatry</i> , 2018, 83, 311-319.	0.7	408
2	Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1408-1420.	13.9	397
3	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.	4.5	304
4	Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. <i>Annals of Neurology</i> , 2015, 77, 953-971.	2.8	282
5	Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. <i>Journal of Nuclear Medicine</i> , 2005, 46, 745-51.	2.8	209
6	ABBY. <i>Neurology</i> , 2018, 90, e1889-e1897.	1.5	188
7	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 21.	3.0	183
8	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
9	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. <i>Alzheimer's and Dementia</i> , 2020, 16, 974-982.	0.4	170
10	Fyn kinase inhibition as a novel therapy for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 8.	3.0	160
11	A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 136-143.	0.6	155
12	The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task. <i>Neuropsychopharmacology</i> , 2000, 23, 240-249.	2.8	131
13	A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 35.	3.0	129
14	Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder. <i>American Journal of Psychiatry</i> , 2002, 159, 309-312.	4.0	127
15	Central Serotonin Transporter Availability Measured With [123 I] β -CIT SPECT in Relation to Serotonin Transporter Genotype. <i>American Journal of Psychiatry</i> , 2004, 161, 525-531.	4.0	122
16	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	3.7	122
17	Age-related decline in central serotonin transporter availability with [123 I] β -CIT SPECT. <i>Neurobiology of Aging</i> , 2000, 21, 497-501.	1.5	115
18	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 1219.	4.5	107

#	ARTICLE	IF	CITATIONS
19	Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. <i>American Journal of Geriatric Psychiatry</i> , 2002, 10, 36-43.	0.6	88
20	The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology. <i>Alzheimer's and Dementia</i> , 2018, 14, 680-691.	0.4	85
21	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
22	Comparing three methods of computerised cognitive training for older adults with subclinical cognitive decline. <i>Neuropsychological Rehabilitation</i> , 2016, 26, 810-821.	1.0	62
23	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. <i>PLoS ONE</i> , 2020, 15, e0229137.	1.1	61
24	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's and Dementia</i> , 2022, 18, 2527-2536.	0.4	55
25	A Responder Analysis of Memantine Treatment in Patients With Alzheimer Disease Maintained on Donepezil. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 428-437.	0.6	54
26	Association of A β 2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [¹¹ C]UCB-J. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 11.	3.0	53
27	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1324.	4.5	51
28	Striatal dopamine transporter availability with [¹²³ I] β -CIT SPECT is unrelated to gender or menstrual cycle. <i>Psychopharmacology</i> , 2005, 183, 181-189.	1.5	46
29	Comparison of [¹¹ C]UCB-J and [¹⁸ F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	2.4	43
30	Classical complement cascade initiating C1q protein within neurons in the aged rhesus macaque dorsolateral prefrontal cortex. <i>Journal of Neuroinflammation</i> , 2020, 17, 8.	3.1	42
31	Striatal dopamine transporters correlate with simple reaction time in elderly subjects. <i>Neurobiology of Aging</i> , 2008, 29, 1237-1246.	1.5	35
32	Absence of an Apolipoprotein E ϵ 4 Allele Is Associated With Increased Parietal Regional Cerebral Blood Flow Asymmetry in Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 1460.	4.9	30
33	Effects of Normative Adjustments to the Montreal Cognitive Assessment. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 1258-1267.	0.6	29
34	PET imaging of mGluR5 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.	3.0	29
35	Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 51-62.	0.6	29
36	Cortical β -amyloid burden, gray matter, and memory in adults at varying APOE ϵ 4 risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 207-214.	1.5	28

#	ARTICLE	IF	CITATIONS
37	Understanding the Latest Advances in Pharmacologic Interventions for Alzheimer's Disease. <i>CNS Spectrums</i> , 2004, 9, 24-28.	0.7	25
38	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	1.5	25
39	The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. <i>Psychopharmacology</i> , 1997, 132, 217-226.	1.5	24
40	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. <i>American Journal of Medical Genetics Part A</i> , 1997, 74, 497-500.	2.4	24
41	Extended-Release Physostigmine in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2000, 57, 157.	13.8	24
42	Exploring Age-Related Changes in Resting State Functional Connectivity of the Amygdala: From Young to Middle Adulthood. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 209.	1.7	23
43	Nicotinic Acetylcholine Receptor Density in Cognitively Intact Subjects at an Early Stage of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 213.	1.7	21
44	Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 232-242.	0.7	20
45	Equilibrium modeling of 5-HT _{2A} receptors with [¹⁸ F]deuterioaltanserin and PET: feasibility of a constant infusion paradigm. <i>Nuclear Medicine and Biology</i> , 2000, 27, 715-722.	0.3	18
46	Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis. <i>NeuroImage</i> , 2021, 237, 118167.	2.1	18
47	Alzheimer disease neuropathology in a patient previously treated with aducanumab. <i>Acta Neuropathologica</i> , 2022, 144, 143-153.	3.9	18
48	Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study. <i>International Psychogeriatrics</i> , 2009, 21, 138.	0.6	17
49	Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. <i>Neurobiology of Aging</i> , 2018, 70, 117-124.	1.5	15
50	Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752210828.	0.9	12
51	Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [¹⁸ F]FPEB PET. <i>NeuroImage</i> , 2021, 238, 118217.	2.1	10
52	Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1251-1265.	1.2	9
53	Amyloid-Associated Depression or Not?. <i>Biological Psychiatry</i> , 2021, 89, 737-738.	0.7	8
54	Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. <i>Psychiatry Research - Neuroimaging</i> , 2021, 317, 111380.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Neuroimaging in Alzheimer's disease: Relevance for treatment. <i>Current Psychiatry Reports</i> , 2001, 3, 13-19.	2.1	7
56	Alzheimer's & Dementia: The Journal of the Alzheimer's Association. <i>Alzheimer's and Dementia</i> , 2021, 17, 316-317.	0.4	7
57	Recruitment of a multi-site randomized controlled trial of aerobic exercise for older adults with amnesic mild cognitive impairment: The EXERT trial. <i>Alzheimer's and Dementia</i> , 2021, 17, 1808-1817.	0.4	5
58	Pleiotropic effects of telomere length loci with brain morphology and brain tissue expression. <i>Human Molecular Genetics</i> , 2021, 30, 1360-1370.	1.4	4
59	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.4	3
60	ICA-derived sources of synaptic density PET ([¹¹ C]UCBâ€) relate to cognitive impairment severity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041197.	0.4	3
61	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.4	2
62	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044211.	0.4	2
63	Imaging Microglial Activation in Alzheimer's Disease: What Does It Mean?. <i>Biological Psychiatry</i> , 2008, 64, 833-834.	0.7	1
64	P1â€69: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P501.	0.4	1
65	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037791.	0.4	1
66	Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [¹¹ C]UCBâ€ PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045928.	0.4	1
67	The calcium-containing smooth endoplasmic reticulum is a focus of risk factors for early and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047651.	0.4	1
68	Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. , 1997, 74, 497.		1
69	Neuroimaging in Alzheimer's Disease: Relevance for the Development of Therapeutic Agents. <i>CNS Neuroscience & Therapeutics</i> , 2000, 6, 26-27.	4.0	0
70	IC-P-108: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODROMAL AD POPULATION. , 2014, 10, P60-P61.		0
71	P3-143: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P680-P681.		0
72	IC-P-101: Amyloid burden is associated with decreased gray matter volume but not episodic memory performance in cognitively normal first-degree relatives at varying ApoE4 risk for Alzheimer's disease. , 2015, 11, P69-P69.		0

#	ARTICLE	IF	CITATIONS
73	P2â€³65: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.	0.4	0
74	P3â€³088: THE AGING RHESUS MONKEY IS AN APPROPRIATE NEW ANIMAL MODEL FOR STUDYING THE ETIOLOGY AND TREATMENT OF TAU PATHOLOGY IN ASSOCIATION CORTEX. Alzheimer's and Dementia, 2018, 14, P1099.	0.4	0
75	ICâ€³04â€³03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.4	0
76	P4â€³013: DESIGN OF A PHASEâ€³ TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD. Alzheimer's and Dementia, 2018, 14, P1436.	0.4	0
77	P1â€³274: A TARGETED MASSâ€³SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P387.	0.4	0
78	ICâ€³Paâ€³183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.	0.4	0
79	P4â€³481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.4	0
80	ICâ€³Paâ€³140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€³TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.4	0
81	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037792.	0.4	0
82	Biochemical characterization of ageâ€³related calciumâ€³cAMPâ€³PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortex. Alzheimer's and Dementia, 2020, 16, e042017.	0.4	0
83	11Câ€³PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043584.	0.4	0
84	Association between cerebral amyloid accumulation and synaptic density in Alzheimerâ€™s disease: A multitracers PET study. Alzheimer's and Dementia, 2020, 16, e043631.	0.4	0
85	Recruitment for a multiâ€³site randomized controlled trial of aerobic exercise for older adults with amnesic mild cognitive impairment: The EXERT trial. Alzheimer's and Dementia, 2020, 16, e044658.	0.4	0
86	Synaptic density is associated with cognitive performance in Alzheimerâ€™s disease: A PET imaging study with [11C]UCBâ€³. Alzheimer's and Dementia, 2021, 17, .	0.4	0
87	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
88	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
89	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
90	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0

#	ARTICLE	IF	CITATIONS
91	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
92	Cognitively unimpaired adultsâ€™ reactions to disclosure of amyloid PET scan results. , 2020, 15, e0229137.		0
93	Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054671.	0.4	0